Legacy is a publication for supporters of the Foundation Fighting Blindness.

Legacy is in PDF format with accessibility features and must be viewed with Adobe Reader in order for these features to be used. If you do not have Acrobat Reader, please click here to download the latest version.


Legacy Spring/Summer 2024

In this issue:

  • A Vision of Hope and Light: Fai and Patrick’s Journey with the Foundation Fighting Blindness
  • All About Beneficiary Designations
  • Beacon Therapeutics Reports Encouraging Interim Results from Phase 2 Clinical Trial for XLRP Gene Therapy
  • Opus Reports Vision Improvements for Patients in LCA5 Gene Therapy Clinical Trial
  • Ascidian to Launch Clinical Trial for Stargardt Disease RNA Editing Therapy
  • jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP
  • VISIONS 2024

Legacy Fall/Winter 2023

In this issue:

  • Legacy Donor Spotlight: Barry Smith & Emily Harding Smith
  • IZERVAY Approved by FDA for Treatment of Geographic Atrophy Secondary to Advanced Dry AMD
  • First Patient Dosed in LCA5 Gene Therapy Clinical Trial Launched by Opus Genetics
  • I Created A Legacy Gift, Now What Do I Do?
  • VISIONS 2024

Legacy Spring/Summer 2023

In this issue:

  • SparingVision Launching Clinical Trial for Cone-Preserving Treatment
  • SYFOVRE™ Now Available for Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
  • Gift Planning: An Issue of Trusts
  • Charity Navigator
  • Impact and Insights Study Insert

Legacy Fall/Winter 2022

In this issue:

  • After Losing Her Husband, Donor With RP Makes Significant Legacy Gift
  • The Reintsma 2025 Legacy Society
  • List of Reintsma Members
  • Hope for Restored Vision through Optogenetics

Legacy Spring/Summer 2022

In this issue:

  • The Karen and Basil Petrou Legacy Education Initiative
  • The Reintsma 2025 Legacy Society Founding Members
  • Chapter Event’s Quest for Cures Also Seeks to Share the Power of Legacy Giving
  • Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies